Skip to main content

Table 3 Univariate Analysis of Prognostic Factors for 73 LAPC patients

From: Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy

Factors

Cases

OS

PFS

Cases

Of

Death

Median

OS

(Month)

95% CI

χ2 Value

P Value

Cases

of Progression

Median PFS

(Month)

95% CI

χ2 Value

P Value

Gender

    

0.010

0.918

   

0.342

0.559

 Male

46

44

14.6

12.9–16.3

  

45

9.8

9.1–10.5

  

 Female

27

23

13.8

12.1–15.5

  

27

9.4

8.0–10.8

  

Age (yrs)

    

2.284

0.131

   

2.041

0.153

  ≤ 68

38

34

15.3

13.8–16.8

  

37

9.4

8.2–10.6

  

 >68

35

33

13.6

12.1–15.1

  

35

10.0

8.3–11.7

  

Presence of DM

    

0.308

0.579

   

0.683

0.409

 No

58

54

13.8

12.1–15.5

  

57

9.6

8.7–10.5

  

 Yes

15

13

14.6

13.7–15.5

  

15

10.8

8.0–13.6

  

ECOG

    

0.485

0.785

   

0.006

0.997

 0

13

12

13.2

9.8–16.6

  

12

9.8

7.1–12.5

  

 1

32

30

13.8

13.0–14.6

  

32

9.6

8.8–10.4

  

 2

28

25

14.7

13.0–16.4

  

28

9.4

8.4–10.3

  

N Stage

    

4.748

0.029*

   

2.267

0.132

 0

40

35

15.1

13.1–17.1

  

40

9.9

6.8–13.0

  

 1

33

32

13.2

12.2–14.2

  

32

9.2

7.9–10.6

  

Tumor Location

    

0.029

0.864

   

0.000

0.990

 Head

51

46

14.6

13.1–16.1

  

50

9.8

9.3–10.3

  

 Body/Tail

22

21

14.0

12.4–15.6

  

22

8.8

7.3–10.3

  

Longest Diameter (cm)

    

4.010

0.045*

   

2.196

0.138

  ≤ 3.7

40

35

14.8

13.7–15.9

  

40

10.0

8.6–11.4

  

 >3.7

33

32

13.2

11.9–14.6

  

32

9.1

7.9–10.3

  

CA19–9 (ng/mL)

    

3.391

0.066

   

3.126

0.077

  ≤ 321.6

37

32

15.3

14.1–16.5

  

36

10.4

9.1–11.7

  

 >321.6

38

35

13.2

11.9–14.5

  

36

8.8

7.2–10.4

  

Radiotherapy Dose (Gy)

    

13.907

<0.001*

   

9.834

0.002*

  ≤ 37.2

37

34

12.2

11.3–13.2

  

36

7.9

7.0–8.9

  

 >37.2

36

33

16.6

15.4–17.8

  

36

11.3

7.8–14.8

  

Chemotherapy

    

7.603

0.006*

   

4.690

0.030*

 No

50

49

13.8

12.7–15.0

  

49

9.5

8.5–10.5

  

 Yes

23

18

16.7

11.5–21.9

  

23

11.3

4.9–17.7

  

SUVmax

    

0.747

0.387

   

0.205

0.651

  ≤ 6.9

38

34

14.7

13.3–16.1

  

38

9.8

8.9–10.7

  

 >6.9

35

33

13.7

12.3–15.1

  

34

9.5

8.3–10.7

  

SUVmean

    

0.310

0.578

   

0.074

0.785

  ≤ 4.0

38

34

14.7

13.3–16.1

  

38

9.8

8.9–10.7

  

 >4.0

35

33

13.7

12.3–15.1

  

34

9.5

8.3–10.7

  

MTV (cm3)

    

4.401

0.036*

   

3.913

0.048*

  ≤ 12.2

37

32

15.6

14.1–17.2

  

36

10.4

9.1–11.7

  

 >12.2

36

35

13.2

11.6–14.8

  

36

8.4

6.5–10.3

  

TLG (g)

    

11.843

0.001*

   

13.777

<0.001*

  ≤ 49.3

36

31

15.9

14.9–16.9

  

35

11.7

8.0–15.4

  

 >49.3

37

36

12.9

12.1–13.7

  

37

7.9

7.0–8.9

  
  1. LAPC locally advanced pancreatic cancer; OS overall survival; PFS progression-free survival; DM diabetes mellitus; ECOG Eastern Cooperative Oncology Group; SUV standard uptake value; MTV metabolic tumour volume; TLG total lesion glycolysis
  2. *: P < 0.05
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us